These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 1431197)

  • 1. Effect of donor Langerhans cells on corneal graft rejection.
    Niederkorn JY; Ross JR; He Y
    J Invest Dermatol; 1992 Nov; 99(5):104S-106S. PubMed ID: 1431197
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The immunogenic privilege of corneal allografts.
    Niederkorn JY; Peeler JS; Ross J; Callanan D
    Reg Immunol; 1989; 2(2):117-24. PubMed ID: 2701814
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The differential effects of donor versus host Langerhans cells in the rejection of MHC-matched corneal allografts.
    Ross J; He YG; Pidherney M; Mellon J; Niederkorn JY
    Transplantation; 1991 Nov; 52(5):857-61. PubMed ID: 1949172
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of cytokine-induced migration of Langerhans cells on corneal allograft survival.
    Niederkorn JY
    Eye (Lond); 1995; 9 ( Pt 2)():215-8. PubMed ID: 7556720
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Langerhans cells, orthotopic corneal allografts, and direct and indirect pathways of T-cell allorecognition.
    Sano Y; Ksander BR; Streilein JW
    Invest Ophthalmol Vis Sci; 2000 May; 41(6):1422-31. PubMed ID: 10798658
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fate of orthotopic corneal allografts in eyes that cannot support anterior chamber-associated immune deviation induction.
    Sano Y; Ksander BR; Streilein JW
    Invest Ophthalmol Vis Sci; 1995 Oct; 36(11):2176-85. PubMed ID: 7558710
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antigen presentation by Langerhans cells in vivo: donor-derived Ia+ Langerhans cells are required for induction of delayed-type hypersensitivity but not for cytotoxic T lymphocyte responses to alloantigens.
    Peeler JS; Niederkorn JY
    J Immunol; 1986 Jun; 136(12):4362-71. PubMed ID: 3519767
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Detection of minor alloantigen-specific cytotoxic T cells after rejection of murine orthotopic corneal allografts: evidence that graft antigens are recognized exclusively via the "indirect pathway".
    Sano Y; Streilein JW; Ksander BR
    Transplantation; 1999 Oct; 68(7):963-70. PubMed ID: 10532535
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An immunodominant minor histocompatibility alloantigen that initiates corneal allograft rejection.
    Haskova Z; Sproule TJ; Roopenian DC; Ksander AB
    Transplantation; 2003 Apr; 75(8):1368-74. PubMed ID: 12717232
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Class I disparate corneal grafts enjoy afferent but not efferent blockade of the immune response.
    Ross J; He YG; Niederkorn JY
    Curr Eye Res; 1991 Sep; 10(9):889-92. PubMed ID: 1790719
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Minor H, rather than MHC, alloantigens offer the greater barrier to successful orthotopic corneal transplantation in mice.
    Sano Y; Ksander BR; Streilein JW
    Transpl Immunol; 1996 Mar; 4(1):53-6. PubMed ID: 8762011
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of cell-mediated immune responses elicited by orthotopic corneal allografts in mice.
    Sonoda Y; Sano Y; Ksander B; Streilein JW
    Invest Ophthalmol Vis Sci; 1995 Feb; 36(2):427-34. PubMed ID: 7843911
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of mismatches for major histocompatibility complex and minor antigens on corneal graft rejection.
    Nicholls SM; Bradley BB; Easty DL
    Invest Ophthalmol Vis Sci; 1991 Sep; 32(10):2729-34. PubMed ID: 1894472
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evidence that the fate of class II-disparate corneal grafts is determined by the timing of class II expression.
    Ross J; Callanan D; Kunz H; Niederkorn J
    Transplantation; 1991 Feb; 51(2):532-6. PubMed ID: 1994550
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Orthotopic corneal transplantation in mice--evidence that the immunogenetic rules of rejection do not apply.
    Sonoda Y; Streilein JW
    Transplantation; 1992 Oct; 54(4):694-704. PubMed ID: 1412761
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immune privilege and immunogenicity reside among different layers of the mouse cornea.
    Hori J; Joyce NC; Streilein JW
    Invest Ophthalmol Vis Sci; 2000 Sep; 41(10):3032-42. PubMed ID: 10967061
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anterior chamber-associated immune deviation promotes corneal allograft survival.
    Niederkorn JY; Mellon J
    Invest Ophthalmol Vis Sci; 1996 Dec; 37(13):2700-7. PubMed ID: 8977485
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The presence of activated donor HLA class I-reactive T lymphocytes is associated with rejection of corneal grafts.
    Roelen DL; van Beelen E; van Bree SP; van Rood JJ; Völker-Dieben HJ; Claas FH
    Transplantation; 1995 Apr; 59(7):1039-42. PubMed ID: 7709440
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Murine orthotopic corneal transplantation in high-risk eyes. Rejection is dictated primarily by weak rather than strong alloantigens.
    Sano Y; Ksander BR; Streilein JW
    Invest Ophthalmol Vis Sci; 1997 May; 38(6):1130-8. PubMed ID: 9152232
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of recipient epithelium in promoting survival of orthotopic corneal allografts in mice.
    Hori J; Streilein JW
    Invest Ophthalmol Vis Sci; 2001 Mar; 42(3):720-6. PubMed ID: 11222533
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.